Atem Nebuliser Solution 2ml – Ipratropium Bromide Bronchodilator for COPD & Asthma

Drug Class: Anticholinergic Bronchodilator | Form: Solution for Nebulisation (Unit Dose Vial — UDV) | Prescription Status: Prescription Only (Rx) | Manufacturer: Chiesi

What Is Atem Nebuliser Solution?

Atem Nebuliser Solution (2ml) is a prescription anticholinergic bronchodilator containing Ipratropium Bromide 0.5mg (500mcg) per vial — equivalent to a 0.025% solution — manufactured by Chiesi for use with a nebuliser. Ipratropium Bromide works by blocking the muscarinic receptors in the smooth muscle of the airways that cause bronchospasm — relaxing and widening constricted airways to make breathing easier.

Unlike beta-2 agonist bronchodilators such as Salbutamol that work through adrenergic stimulation, Ipratropium works through a completely different anticholinergic mechanism — making it a valuable standalone treatment and a clinically important addition to beta-2 agonist therapy when greater bronchodilation is required. Its action is sustained and relatively prolonged compared to short-acting beta-2 agonists, with bronchodilation lasting up to 6 to 8 hours after nebulisation.

Atem is primarily used in the long-term management of COPD and as an adjunct in asthma management, and must only be used under medical supervision with a valid prescription.

What Is Atem Nebuliser Solution Used For?

Atem Nebuliser Solution is prescribed for:

• Chronic Obstructive Pulmonary Disease (COPD — پھیپھڑوں کی دائمی بیماری) — long-term bronchodilator maintenance therapy for patients with chronic bronchitis and emphysema to reduce airflow obstruction and improve breathing capacity
• Bronchial asthma — particularly moderate to severe asthma where anticholinergic bronchodilation is required alongside or instead of beta-2 agonist therapy
• Acute severe asthma exacerbations — combined with Salbutamol nebulisation for greater bronchodilation during hospital or clinic management of severe acute asthma
• Acute COPD exacerbations — increased frequency nebulisation during acute worsening of COPD symptoms under medical supervision
• Chronic bronchitis with reversible airway obstruction — relief of bronchospasm in patients with chronic productive cough and airflow limitation
• Patients intolerant of beta-2 agonists — Ipratropium's entirely different mechanism makes it the bronchodilator of choice when Salbutamol or similar agents are not tolerated

How Does Atem Nebuliser Solution Work?

Ipratropium Bromide 0.5mg — Anticholinergic Bronchodilator: The airways are under constant influence from the parasympathetic nervous system — which releases acetylcholine that binds to muscarinic receptors on airway smooth muscle, causing bronchoconstriction and increased mucus secretion. In patients with COPD and asthma, this cholinergic tone is a significant contributor to airway narrowing and breathlessness.

Ipratropium Bromide is a quaternary ammonium anticholinergic compound that competitively blocks muscarinic receptors — specifically M1 and M3 subtypes — on airway smooth muscle and mucous glands. By occupying these receptors, Ipratropium prevents acetylcholine from binding and triggering bronchoconstriction. The airway smooth muscle relaxes, the airway lumen widens, airflow resistance decreases, and breathing becomes significantly easier.

Key Pharmacological Advantages of Ipratropium: Because Ipratropium is a quaternary ammonium compound, it is poorly absorbed across biological membranes — meaning it acts almost entirely locally within the airways with very limited systemic absorption. This localised action is what gives Ipratropium its excellent safety profile compared to older systemic anticholinergic drugs — the bronchodilatory benefit is achieved with minimal cardiovascular, central nervous system, or urinary side effects at standard doses.

Ipratropium's onset of bronchodilation begins within 5 to 15 minutes of nebulisation, reaches peak effect at 1 to 2 hours, and is sustained for 6 to 8 hours — a significantly longer duration than Salbutamol's 4 to 6 hours — making it particularly valuable for maintenance bronchodilator therapy requiring less frequent dosing.

Complementary Action with Salbutamol: Ipratropium and Salbutamol act on entirely different receptors through independent pathways. When combined — either as separate nebulisations or as a fixed combination — they produce additive bronchodilation that is measurably greater than either agent alone. This combination is a cornerstone of management for both acute severe asthma and COPD exacerbations in clinical practice.

Dosage and Administration

⚠️ Use exactly as prescribed. Never exceed the prescribed dose — higher doses do not produce proportionally greater bronchodilation but do increase side effect risk. Avoid contact with the eyes during nebulisation — always use a mouthpiece rather than a face mask where possible. Keep a fast-acting reliever available for acute attacks.

How to Use with a Nebuliser:

1. Wash hands thoroughly before handling vial and nebuliser equipment
2. Twist and open one UDV vial — use entire 2ml contents
3. Pour vial contents into the nebuliser chamber — may be mixed with Salbutamol nebuliser solution if prescribed together
4. Use a mouthpiece rather than a face mask wherever possible — to prevent Ipratropium solution contact with the eyes
5. If a face mask must be used — in young children or very unwell patients — ensure it fits snugly and close eyes during nebulisation
6. Breathe slowly and deeply through the mouth until the chamber is empty — typically 5 to 10 minutes
7. Clean the nebuliser chamber after every use per manufacturer's instructions
8. Use each vial immediately after opening — do not store opened vials

Active Ingredients

Who Should NOT Use Atem Nebuliser Solution?

Do not use Atem if you:

• Are allergic to Ipratropium Bromide, Atropine, or any other anticholinergic drug or ingredient in this product
• Have known hypersensitivity to soya or peanut — some Ipratropium formulations contain soya-derived lecithin; confirm with your pharmacist
• Are using Atem as the sole treatment for acute severe asthma — Ipratropium must be used alongside beta-2 agonists and systemic steroids in acute severe asthma managed in a clinical setting

Always consult your doctor before use if you:

• Have narrow-angle glaucoma — accidental eye contact with Ipratropium can precipitate acute angle-closure glaucoma (eye pain, blurred vision, halos — seek emergency eye care immediately)
• Have benign prostatic hyperplasia (BPH) or bladder outflow obstruction — anticholinergic drugs can worsen urinary retention
• Have cystic fibrosis — may increase risk of gastrointestinal motility disturbance
• Are pregnant or breastfeeding — use only when benefit clearly outweighs risk
• Have cardiovascular disease — use with caution at higher doses

Side Effects

Common (mild):

• Dry mouth (خشک منہ) — most common anticholinergic side effect; drink water regularly during treatment
• Mild headache
• Mild nausea or stomach discomfort
• Mild throat irritation or cough during nebulisation

Serious — Stop Use and Seek Medical Attention Immediately:

• Acute angle-closure glaucoma — if Ipratropium solution contacts the eyes: sudden severe eye pain, blurred vision, red eye, halos around lights, headache — this is a medical emergency requiring immediate ophthalmological treatment (یہ طبی ہنگامی صورتحال ہے)
• Urinary retention — difficulty or inability to urinate — particularly in men with existing prostate problems
• Paradoxical bronchospasm — worsening breathlessness immediately after nebulisation — stop immediately and use emergency reliever; seek urgent medical attention
• Tachycardia or palpitations — fast or irregular heartbeat; report to doctor promptly
• Severe allergic reaction — rash, swelling of face or throat, difficulty breathing (یہ طبی ہنگامی صورتحال ہے)

Drug Interactions

Storage Instructions

• Store below 25°C in a cool, dry place
• Protect UDV vials from direct sunlight — store in original foil pouch until use
• Do not freeze
• Use each vial immediately after opening — never store opened vials
• Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں)
• Do not use after the expiry date on the vial or carton

Frequently Asked Questions

How is Ipratropium different from Salbutamol — and when are both used together?

Salbutamol is a beta-2 agonist that stimulates adrenergic receptors on airway smooth muscle to cause rapid bronchodilation — it acts within minutes and is the first-choice reliever for acute bronchospasm. Ipratropium is an anticholinergic that blocks muscarinic receptors to prevent cholinergic bronchoconstriction — its onset is slightly slower but its duration is longer. Because they work through entirely different pathways on different receptors, combining them produces additive bronchodilation significantly greater than either alone. This combination is standard practice in acute severe asthma and COPD exacerbations in clinical settings, and is commonly prescribed for maintenance therapy in COPD where maximum bronchodilation is required.

Why is avoiding eye contact with Atem solution so important?

Accidental contact of Ipratropium solution with the eyes can precipitate acute angle-closure glaucoma — a serious eye emergency characterised by sudden severe eye pain, dramatically blurred vision, red eye, halos around lights, and headache. This occurs because Ipratropium blocks the muscarinic receptors controlling the eye's drainage system, causing a sudden dangerous rise in intraocular pressure. This is why using a mouthpiece rather than a face mask is strongly preferred — and why, if a face mask must be used, it must fit snugly and the eyes should be closed throughout nebulisation. If any eye symptoms develop after Atem use, seek emergency ophthalmological attention immediately.

Can Atem be mixed with Salbutamol in the same nebuliser?

Yes — Ipratropium Bromide solution is physically compatible with Salbutamol nebuliser solution and the two are routinely combined in the same nebuliser chamber when both are prescribed together. This is a common and clinically established practice for both COPD maintenance and acute asthma management. Always confirm with your doctor or pharmacist that your specific products are compatible before mixing, and use the combined solution immediately — never store mixed solutions.

Is Atem suitable for long-term daily use in COPD?

Yes — Ipratropium Bromide is specifically indicated for long-term maintenance bronchodilator therapy in COPD and is one of the foundational treatments in COPD management guidelines. Unlike beta-2 agonists, tolerance to Ipratropium's bronchodilatory effect does not develop with regular use — maintaining its effectiveness with long-term daily therapy. Regular review by your doctor is still important to assess whether your COPD management is optimally controlling symptoms and whether additional or alternative therapies are needed.

I have an enlarged prostate — is Atem safe for me?

Ipratropium's anticholinergic mechanism can worsen urinary symptoms in men with benign prostatic hyperplasia by reducing bladder muscle contractility and increasing the risk of urinary retention. If you have BPH or any history of difficulty urinating, inform your doctor before starting Atem. In many cases Ipratropium can still be used with monitoring, but your doctor needs to weigh the bronchodilatory benefit against the risk of worsening urinary symptoms for your specific situation.

---

⚕️ Medical Disclaimer: This product description is for general informational purposes only and does not replace professional medical advice. Atem is a prescription medication — always use under the supervision of a qualified doctor or respiratory specialist. Avoid eye contact with nebuliser solution — if eye symptoms develop after use, seek emergency ophthalmological attention immediately. Always keep a fast-acting emergency reliever available alongside scheduled Atem therapy.

---

Prescription Required (Rx) | Manufactured by Chiesi | Use Mouthpiece to Avoid Eye Contact | Keep Emergency Reliever Available | Do Not Store Opened Vials